Drug profile

The FDA adverse-event record for Unspecified Topical Flea Product

24 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Unspecified Topical Flea Product. See the species affected, top reactions, and outcomes below.

24
adverse-event reports
4.2%
death-coded share
Cat
most-reported species
17
Lack of efficacy (ectoparasite) - flea - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
24
Total Reports
1
Deaths Reported
4.2%
Death Rate

Active Ingredients

Unspecified Topical Flea Product

Administration Routes

TopicalUnknown

Species Affected

Cat 13
Dog 11

Most Affected Breeds

Domestic Shorthair 8
Spitz - German Pomeranian 2
Mixed (Cat) 2
Shepherd Dog - German 1
Pit Bull 1
Shih Tzu 1
Himalayan 1
Papillon - Spaniel - Continental Toy (with erect ears or with dropped ears (Phaléne)) 1
Retriever - Golden 1
Dachshund - Miniature 1

Most Reported Reactions

Lack of efficacy (ectoparasite) - flea 17
Hyperactivity 4
Vocalisation 2
Panting 2
Pruritus 1
Lethargy (see also Central nervous system depression in 'Neurological') 1
Lack of efficacy - NOS 1
Mewing 1
Licking 1
Agitation 1
Warm feeling to the touch 1
Twitching 1

Outcome Breakdown

Outcome Unknown
14 (58.3%)
Recovered/Normal
6 (25.0%)
Ongoing
3 (12.5%)
Euthanized
1 (4.2%)

Unspecified Topical Flea Product Adverse Event Insights

24 reports name Unspecified Topical Flea Product; 1 recorded a death outcome (4.2% of reported events, not a population-level mortality rate). Active ingredient: Unspecified Topical Flea Product. Administration routes: Topical, Unknown.

By species: Cat (13 reports), Dog (11 reports). By breed: Domestic Shorthair (8), Spitz - German Pomeranian (2), Mixed (Cat) (2).

Leading clinical signs: Lack of efficacy (ectoparasite) - flea (17), Hyperactivity (4), Vocalisation (2), Panting (2). Outcome, 24 coded reports: Outcome Unknown leads at 58.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.